Linden LLC

Pat Noland Appointed StrataDx Chief Executive Officer

November 8, 2011 | For Immediate Release

Lexington, Massachusetts , (November 8, 2011) – StrataDx, a leader in anatomic pathology, has named former LabCorp executive, Pat Noland, CEO. Since 1984, StrataDx has partnered with clinicians to provide the best care to patients through its high-quality pathology services in the dermatology, urology, podiatry, oral pathology, gastroenterology, and gynecology segments.

Mr. Noland’s appointment is a key milestone for StrataDx following the recent equity investment by Linden Capital Partners. According to Brian Miller, a member of the StrataDx board and Linden managing partner, “Pat is the ideal leader to take StrataDx to the next level as it broadens its testing menu to include the latest in molecular pathology and expands its outreach to bring Strata’s best-in-class client service and clinical expertise to a significantly wider customer base.”

Mr. Noland joins StrataDx after 17 years at the $5 billion clinical-laboratory company, Laboratory Corporation of America (LabCorp). Mr. Noland was most recently senior vice president responsible for developing and implementing LabCorp’s hospital strategy. Previously, Mr. Noland held full P&L responsibility for DIANON Systems, LabCorp’s anatomic pathology business, as well as a series of other senior leadership roles.

“I’m thrilled to join StrataDx, which is exceptionally positioned for growth,” commented Noland. “World-renowned dermatopathologist and educator, Geoffrey Gottlieb, M.D., has joined Terence Harrist, M.D. as co-director of Strata’s dermatopathology department, placing two of the leading dermatopathologists in the same practice. Additionally, we have experienced impressive growth in other specialties due to our quality, expertise, and focus on the customer and patient. We look forward to expanding those services beyond our core geographic market.”